Intraventricular Administration of Substance P Increases the Dendritic Arborisation and the Synaptic Surfaces of Purkinje Cells in Rat's Cerebellum

References

• Armstrong D., Terry R. D. Substance P immunoreactivity within neuritic plaques. Neuroscience Letters 1986; 58: 139–144
   Web of Science ®Google Scholar
• Baloyannis S. J. The Purkinje cell of the Human Cerebellum. Thesis, Aristotelian University of Thessaloniki. 1975
   Google Scholar
• Baloyannis S. J., Costa V., Deretzi G. Intraventricular administration of Substance P induces unattached Purkinje cell dendritic spines. International Journal of Neuroscience 1992; 62: 251–262
   PubMedGoogle Scholar
• Baloyannis S. J., Gonatas N. K. Distribution of anti‐HRP antibodies in CNS of immunized rats after disruption of the blood brain barrier. Journal of Neuropathology: & Experimental Neurology 1979; 38: 519–531
   PubMed Web of Science ®Google Scholar
• Baloyannis S. J., Kim S. U. Experimental modification of cerebellar development in tissue culture: X‐irradiation induces granule cell degeneration and unattached Purkinje cell dendritic spines. Neuroscience Letters 1979; 12: 283–288
   PubMed Web of Science ®Google Scholar
• Baloyannis S. J., Kim S. U. Morphological alteration of Purkinje cell axons and presynaptic terminals in organotypic cerebellar cultures exposed to ionizing irradiation. Acta Neuropathologica (Berlin) 1981; 54: 301–310
   PubMed Web of Science ®Google Scholar
• Baloyannis S. J., Karakatsanis K., Apostolakis M., Diacoyannis A. Effects of GABA, glycin and sodium barbiturate on dendritic growth in vitro. Acta Neuropathologica (Berlin) 1983; 59: 171–182
   PubMed Web of Science ®Google Scholar
• Baruch P., Artaud F., Godeheu G., Barbeito L., Glowinski J., Cheramy A. Substance P and neurokin A regulate by different mechanisms dopamin release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons. Neuroscience 1988; 25: 889–898
   PubMedGoogle Scholar
• Beal N., Masurek M. Substance P like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 1987; 37: 1205–1207
   PubMed Web of Science ®Google Scholar
• Beech T., Me Greer E. G. Neocortical substance P neurons in the baboon: an immunohistochemical finding. Neuroscience Letters 1983; 41: 265–270
   PubMed Web of Science ®Google Scholar
• Blum A., Elliott D., Metwali A., Qadir K., Joel V. Substance P regulates somatostatin expression in inflammation. The Journal of Immunology 1998; 161: 6316–6322
   PubMedGoogle Scholar
• Bost K. L., Pascual D. W. Substance P: a late‐acting B lymphocyte differentiation cofactor. American Journal of Physiology 1992; 262: 537–545
   PubMed Web of Science ®Google Scholar
• Brown J. R., Hill R. G. Multiple receptors for substance P. Trends of Neuroscience 1983; 4: 512–514
   Google Scholar
• Brownstein M. J., Mroz E. A., Tappaz M. L., Leeman S. E. On the origin of substance P and glutamic acid decarboxylase (GAD) in the substantia nigra. Brain Research 1977; 35: 315–323
   Google Scholar
• Buck S. H., Heikc C. J., Burcher E., Shults C., O'Donohue T. L. Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinines in the central nervous system. Peptides 1986; 1: 1109–11120
   Google Scholar
• Chang M. M., Leeman S. E. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. Journal of Biological Chemistry 1970; 245: 4784–4790
   PubMed Web of Science ®Google Scholar
• Chang M. M., Leeman S. E., Niall H. D. Amino acid sequence of substance P. Nature 1971; 232: 86–87
   PubMed Web of Science ®Google Scholar
• Cheramy A., Michelot R., Leviel V., NieouIIon A., Glowinski J., Kerdelhue B. Effect of the immunoneutralization of substance P in the cat substantia nigra on the release of dopamine from dendrites and terminals of dopaminergic neurons. Brain Research 1978; 155: 404–408
   PubMed Web of Science ®Google Scholar
• Constantinides J., Bouras C., Richard J. Putative peptide neurotransmitters in human neuropathology. Topography and clinical implication. Clinical Neuro‐pathology 1983; 2: 47–54
   Google Scholar
• Crystal H. A., Davies P. Cortical substance P‐like immunoreactivity in cases of Alzheimer's disease and senile dementia of Alzheimer's type. Journal of Neurochemistry 1982; 38: 1781–1784
   PubMed Web of Science ®Google Scholar
• Cuello A. C., Pristley J. V., Matthews M. R. Localization of substance P in neuronal pathways. Ciba Foundation Symposium 1982; 91: 55–83
   Google Scholar
• Espamer V. The tachykinin peptide family. Trends of Neurosciences 1981; 4: 267–269
   Web of Science ®Google Scholar
• Hall M., Stewart J. The substance P Fragment SP (1–7) stimulates motor behaviour and nigral dopamine release. Pharmacology Biochemistry & Behaviour 1991; 41: 75–78
   Google Scholar
• Han Y., Shaikh M., Siegel A. Medial amygdaloid suppression of pedatory attack behaviour in the rat: I Role of a substance P pathway from the medial amygdala to the medial hypothalamus. Brain Research 1996; 716: 59–71
   PubMedGoogle Scholar
• Harmar A., Schofield J. G., Keer P. Substance P biosynthesis in dorsal root ganglia: an immunochemical study of 35J methionin and 3H proline incorporation in vitro. Neuroscience 1981; 6: 1917–1922
   PubMed Web of Science ®Google Scholar
• Hartung H. P., Heininger K., Scaefer B., Toyka K. Substance P stimulates release of arachidonic acid cycloxygenation products from primary cultured rat astrocytes. Annals of New York Academy of Sciences 1988; 540: 427–429
   PubMedGoogle Scholar
• Hasenohrl R., Jentjens O., De Souza Silva M., Tomaz C., Huston J. Anxiolytic‐like action of neurokinin substance P administered systematically or into the nucleus basalis magnocellularis region. European Journal of Pharmacology 1998; 354: 129–133
   Google Scholar
• Heath M., Lints T., Justin L., Dodd J. Functional expression of the tachykinin NK 1 receptor by floor plate cells in the embryonic rat spinal cord and brain stem. Journal of Physiology 1995; 486: 139–148
   PubMedGoogle Scholar
• Heike C., Charlton C., Wiley R. Studies on the cellular localization of spinal cord substance P receptors. Neuroscience 1988; 19: 523–533
   Google Scholar
• Hokfelt T., Meyerson B., Nillson G., Pernow B., Sachs C. Immunohisto‐chemical evidence for substance P containing nerve endings in the human cortex. Brain Research 1976; 104: 181–186
   PubMed Web of Science ®Google Scholar
• Hokfelt T., Ljungdahl A., Terrentius L., Elde R., Nilsson G. Immunohis‐tochemical analysis of peptide pathways possibly related to pain and analgesia:encephalin and substance P. Proceedings of the National Academy of USA 1977; 74: 3881–3885
   Google Scholar
• Holtzer‐Petsche U., Schimek E., Amann R., Lembeck F. In vivo and in vitro actions of mammalian tachykinins. Naunyn Schmiedeberg's Archives of Pharmacology 1985; 330: 130–135
   PubMedGoogle Scholar
• Igwe B., Sum X., Larson A. Role of substance P amino‐terminal metabolites in substance P induced desensitization in mice. Neuroscience 1990; 36: 535–542
   PubMed Web of Science ®Google Scholar
• Inagaki S., Sakanaka M., Shiosaka S., Senba E., Takagi H., Takatsuki K., Kawai Y., Matsusaki T., Ida H., Hara Y., Tohyama M. Experimental and immunohistochemical studies on the substance P of the rat: localization, postnatal ontogeny and ways of entry to the cerebellum. Neuroscience 1982; 7: 639–645
   PubMedGoogle Scholar
• Iversen S. D. Behavioural effects of substance P through dopaminergic pathways in the brain. Ciba Foundation Symposium 1982; 91: 307–324
   Google Scholar
• Kaneko T., Shigemoto R., Nakanishi S., Mizuno N. Morphological and chemical characteristics of substance P receptor‐immunoreactive neurons in the rat neocortex. Neuroscience 1994; 60: 199–211
   PubMedGoogle Scholar
• Karlson K., Eriksson U., Andren P., Nyberg F. Purification and characterization of substance P endopeptidase activities in the rat spinal cord. Preparation of Biochemistry & Biotechnology 1997; 27: 59–78
   PubMedGoogle Scholar
• Kelley A., Iversen S. Behavioral responses to bilateral injections of substance P into the substantia nigra of the rat. Brain Research 1978; 158: 474–478
   PubMedGoogle Scholar
• Kewaja M., Flumerfelt B., Hunt S., Hrycyshyn A. Substance P immunoreactivity in the rat interpeduncular nucleus: synaptic interactions between substance P‐positive profiles and choline acetytransferase‐or glutamate decarbox‐ylase‐immunoreactive structures. Neuroscience 1991; 42: 739–755
   PubMedGoogle Scholar
• Khan S., Brooks N., Whelpton R., Michael‐Titus A. T. Substance P‐(l‐7) and substance P‐(5–11) locally modulate dopamine release in rat striatum. European Journal of Pharmacology 1995; 282: 229–233
   PubMedGoogle Scholar
• Khan S., Grogan E., Whelpton R., Michael‐Titus A. N‐and C‐terminal substance P fragments modulate striatal dopamine outflow through a cholinergic link mediated by muscarinic receptors. Neuroscience 1996; 73: 919–927
   PubMedGoogle Scholar
• Kramer M., Cutler N., Feighner J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640–1645
   PubMed Web of Science ®Google Scholar
• Lavielle S., Chassaing G., Julien S., Besseyrc J., Marquet A. The influence of the amino acids of substance P in the recognition of receptor affinities of synthesized SP analogues for the specific 125 J‐BHSP binding sites on the brain synaptosomes. Neuropeptide 1986; 7: 191–200
   PubMed Web of Science ®Google Scholar
• Lembeck F., Holzer P. Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Nauyn Schmiedelberg's Archives of Pharmacology 1981; 310: 175–183
   Google Scholar
• Louis J. C., Rougeot C., Bepoldin O., Vulliez B., Mandel P., Dray L. Presence of somatostatin, encephalin and substance P‐like peptides in cultured neurons from embryonic chick cerebral hemispheres. Journal of Neurochemistry 1983; 41: 930–938
   PubMed Web of Science ®Google Scholar
• Maggio J. Tachykinins. Annual Review of Neuroscience 1988; 11: 13–28
   PubMed Web of Science ®Google Scholar
• Mai J. K., Stephens P., Hopf A., Cuello A. C. Substance P in human brain. Neuroscience 1986; 17: 709–739
   PubMedGoogle Scholar
• Manolides L., Baloyannis S. J. The neuropeptides in the acoustic cortex. 1. Substance P. Acta Otolaryngologica (Stockholm) 1987; 103: 481–488
   PubMedGoogle Scholar
• Manolides L., Baloyannis S. J., Manolides S. Substance P increases the polymorphism of the synaptic vesicles in the temporal isocortex cultured in vitro. Acta Otolaryngologica (Stockholm) 1988; 105: 500–506
   PubMed Web of Science ®Google Scholar
• Manolides L., Baloyannis S. J., Manolides S. Substance P in the acoustic area of the cortex during neuronal development and maturation. Acta Otolaryngologica. (Stockholm) 1989; 107: 375–382
   PubMedGoogle Scholar
• Martone M. E., Armstrong D. M., Young S. J., Groves P. M. Cholinergic neurons are distributed preferentially in areas rich in substance P‐like immuno‐reactivity in the caudate nucleus of the adult cat. Neuroscience 1993; 56: 567–579
   PubMedGoogle Scholar
• Matsumoto S., Goto S., Mizusawa H., Hirano A. Immunohistochemical study of substance P and methencephalin in the globus pallidus of progressive supranuclear palsy (PSP). Journal of Neuropathology & Experimental Neurology 1989; 48: 325
   Web of Science ®Google Scholar
• Melis M. R., Gale K. Evidence that nigral substance P controls the activity of the nigrotectal GABA‐ergic pathway. Brain Research 1984; 295: 389–393
   Web of Science ®Google Scholar
• Mroz E. A., Brownstein M. J., Leeman S. E. Evidence for substance P in the habenulo‐interpeduncular tract. Brain Research 1976; 113: 597–599
   PubMed Web of Science ®Google Scholar
• Mroz E. A., Brownstein M. J., Leeman S. E. Evidence for substance P in the striatonigral tract. Brain Research 1977; 125: 305–311
   PubMed Web of Science ®Google Scholar
• Nakanishi S. Mammalian Tachykinine Receptors. Annual Review of Neuroscience 1991; 14: 123–126
   PubMed Web of Science ®Google Scholar
• Nakata Y., Kusaka Y., Yajima H., Segawa T. Active uptake of substance P carboxy terminal heptapeptide (5–11) into rat brain and rabbit spinal cord slices. Journal of Neurochemistry 1981; 37: 1529–1534
   PubMed Web of Science ®Google Scholar
• Napier T., Mitrovic I., Churchill L., Klitenick M., Lu X., Kalivas R. Substance P in the ventral pallidum: projection from the ventral striatum and electrophysiological and behavioural consequences of pallidal substance P. Neuroscience 1995; 69: 59–70
   PubMedGoogle Scholar
• Nicoll R. A., Schenker C., Leeman S. E. Substance P as a transmitter candidate. American Review of Neuroscience 1980; 3: 227–268
   PubMed Web of Science ®Google Scholar
• Nielson J., von Euler A. M., Dalsgaard C. J. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985; 315: 61–63
   PubMed Web of Science ®Google Scholar
• Nishida T., Nakamura M., Koma T., Ofugi K., Nagano K., Tanaka T., Enoki M., Reid T., Brown S., Murphy C., Mannis M. Neurotrophic keratopathy studies on substance P and the clinical significance of corneal sensation. Nippon Gakkai Zasshi 1997; 101: 948–974
   Google Scholar
• Payan D., Brewster D., Missirian‐Bastian A., Goetzl E. Substance P recognition of human T lymphocytes. Journal of Clinical Investigation 1984; 74: 1532–1539
   PubMed Web of Science ®Google Scholar
• Payan D. G. Receptor‐mediated mitogenic effects of substance P on cultured smooth muscle cells. Biochemical & Biophysical Research Communication 1985; 30: 104–109
   Google Scholar
• Payan D. G., McGillis J. P., Renold F. K., Mitsubashi M., Goetzl E. J. Neuropeptide modulation of leucocyte function. Annals of New York Academy of Sciences 1987; 496: 182–191
   PubMed Web of Science ®Google Scholar
• Payan D. G., McGillis J. P., Renold F. K., Mitsubashi M., Goetzl E. J. The immunomodulating properties of neuropeptides. Hormones & Immunity, J. Berczi, K. Kovacs. MTP Press, Nowell, MA 1987; 203–214
   Google Scholar
• Payan D. G. Neuropeptides and inflammation: The role of substance P. Annual Review of Medicine 1989; 40: 341–352
   PubMed Web of Science ®Google Scholar
• Pearson J., Brandeis L., Cuello A. C., Johnson E. Selective depletion of substance P in familial dysautonomia and nerve growth factor deprived animals. Journal of Neuropathology & Experimental Neurology 1981; 40: 339
   Web of Science ®Google Scholar
• Pearson J., Brandeis L., Cuello A. C. Depletion of substance P containing axons in substantia gelatinosa of patients with diminished pain sensitivity. Nature 1982; 295: 61–63
   PubMed Web of Science ®Google Scholar
• Pearson J., Goldstein M., Brandeis L., Gucllo A. Complexity of human mesencephalic catecholamine neurons and substance P terminals: change in diseases. Journal of Neuropathology & Experimental Neurology 1982; 41: 361
   Web of Science ®Google Scholar
• Pradelles P., Gross C., Humbert J., Dray F., Ben‐Ami Y. Visual deprivation decreases metencephalin and substance P content of various forbrain structures. Brain Research 1979; 1966: 191–193
   Google Scholar
• Quigley B. J., Kowall N. W. Substance P‐like immunoreactivity neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience 1991; 41: 41–60
   PubMed Web of Science ®Google Scholar
• Rikard‐Bell G. C., Tork I., Sullivan C., Scheibner T. Distribution of substance P‐like immunoreactive fibres and terminals in the medulla oblongata of the human infant. Neuroscience 1990; 34: 133–148
   PubMed Web of Science ®Google Scholar
• Reid M., Herrera‐Marschitz M., Hokfelt T., Ohlin M., Valentino K., Ungerstedt U. Effects of intranigral substance P and neurokinin A on striatal Dopamine release‐I Interactions with substance P antagonists. Neuroscience 1990; 36: 643–658
   PubMed Web of Science ®Google Scholar
• Sakuma M., Yoshioka K., Suzuki H., Yanagisawa M., Onishi Y., Kobayashi N., Otsuka M. Substance P‐evoked release of GABA from isolated spinal cord of the newborn rat. Neuroscience 1991; 45: 323–330
   PubMedGoogle Scholar
• Serres L., Leranth C. Distribution of substance P‐immunoreactive neurons and fibres in the monkey hippocampal formation. Neuroscience 1996; 71: 633–650
   PubMedGoogle Scholar
• Sharma S. H., Nyberg F., Olsson Y., Dey P. K. Alteration of substance P after trauma to the spinal cord:an experimental study in the rat. Neuroscience 1990; 38: 205–212
   PubMed Web of Science ®Google Scholar
• Sharp T., Zetterstorm T., Ungerstedt U. An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. Journal of Neurochemistry 1986; 47: 113–122
   PubMed Web of Science ®Google Scholar
• Staubli U., Huston J. Facilitation of learning by post‐trial injection of substance Pinto the medial septal nucleus. Behavioural Brain Research 1980; 1: 245–255
   PubMed Web of Science ®Google Scholar
• Takahasi K., Sakurada T., Sakurada S., Kuwahara H., Yonezawa A., Ando R., Kisara K. Behavioural characterization of substance P‐induced responses in mice. Neuropharmacology 1987; 26: 1289–1293
   PubMedGoogle Scholar
• Tanaka C., Taniyama K. Substance P provoked gamma‐aminobutyric acid release from the myenteric plexus of the guinea‐pig small intestine. Journal of Physiology (London) 1985; 362: 319–329
   PubMedGoogle Scholar
• Torrens Y., Beaujouan J., Saffroy M., Daquet de Mocety M., Bergstrom L., Glowinski J. Substance P receptors in primary cultures of cortical astrocytes from the mouse. Proceedings of the National Academy of Sciences of USA 1986; 83: 9216
   PubMed Web of Science ®Google Scholar
• Van Winersma Greidanus, Maigert C. Grooming behaviour induced by substance P. European Journal of Pharmacology 1988; 154: 217–220
   PubMedGoogle Scholar
• Vincent S. R., Satoh K., Armstrong D. M., Fibiger H. C. Substance P in ascending cholinergic reticular system. Nature 1983; 306: 588–691
   Web of Science ®Google Scholar
• von Euler V. S., Gaddum J. H. An unidentified depressor substance in certain tissue extracts. Journal of Physiology 1931; 72: 577–583
   Google Scholar
• Werge T. M. Identification of an epitope in the substance P receptor important for recognition of the common carboxyl‐terminal tachykinin sequence. Journal of Biological Chemistry 1994; 269: 22054–22058
   PubMedGoogle Scholar
• Yung K., Tang F., Fielding R., Vacca‐Galloway L. Alterations in the level of thyrotrophin releasing hormone, substance P and encephalins in the spinal cord, brainstem, hypolhalamus and midbrain of the Wobber mouse at different stages of the motor neuron disease. Neuroscience 1992; 50: 209–222
   PubMedGoogle Scholar